Tevogen Inc.

Name: Tevogen Inc. standardized financial statements, quarterly
Creator: Listed

TVGNNasdaqCIK 1860871HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$5.7m, Q2 FY2026

Net income−$5.8m, Q2 FY2026

Tevogen Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Research and development	$m	1.1	0.9	20.8	4.1	3.3	2.8	3.2	2.7	3.1	2.1	3.1	3.3
Operating income	$m	(2.3)	(2.0)	(29.5)	(8.6)	(6.1)	(9.4)	(10.4)	(5.4)	(5.7)	(4.6)	(5.4)	(5.7)
Interest expense	$m	0.3	0.3	0.2	not reported	0.0	0.0	0.0	not reported	not reported	not reported	not reported	not reported
Net income	$m	(3.9)	(3.6)	11.3	(9.7)	(5.9)	(9.4)	(10.4)	(5.5)	(5.7)	(4.7)	(5.4)	(5.8)
Diluted EPS	$ per share	(0.03)	not reported	(0.26)	(0.04)	(0.03)	not reported	(3.25)	(1.71)	(0.03)	not reported	(1.61)	(1.52)
Basic EPS	$ per share	(0.03)	not reported	0.08	(0.04)	(0.03)	not reported	(3.25)	(1.71)	(0.03)	not reported	(1.61)	(1.52)

Balance sheet

Cash and equivalents$1.1m, Q2 FY2026

Shareholders' equity−$8.9m, Q2 FY2026

Tevogen Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	25.0	0.0	1.3	1.1	2.3	0.0	2.0	0.7	1.0	0.0	0.7	1.1
Current assets	$m	0.4	1.7	2.4	2.4	3.5	2.4	3.1	2.1	2.1	1.5	2.1	2.0
Total assets	$m	26.4	5.5	3.4	3.3	4.3	3.5	4.1	4.3	4.5	4.4	4.9	4.7
Current liabilities	$m	1.8	85.5	8.9	10.6	10.4	9.0	8.7	8.1	6.7	7.1	7.3	6.2
Total liabilities	$m	16.6	99.9	9.2	10.9	10.5	10.1	11.8	13.8	12.3	12.6	14.8	13.6
Short-term borrowings	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	(90.8)	(94.4)	(5.8)	(7.7)	(6.2)	(6.7)	(7.7)	(9.5)	(7.8)	(8.2)	(9.8)	(8.9)

Cash flow

Operating cash flow−$3.0m, Q2 FY2026

Capital expenditure$0, Q4 FY2023

Share repurchases$9.7m, Q4 FY2023

Tevogen Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(1,800)	(1,976)	(2,164)	(2,983)	(3,805)	(3,048)	(3,308)	(3,190)	(3,650)	(2,181)	(2,734)	(3,005)
Capital expenditure	$k	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Share repurchases	$k	0.0	9,714	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)3.83m, Q2 FY2026

Tevogen Inc., shares, quarterly
Line item	Unit	Q1 FY20222022-03-31	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	36.0	120	120	120	142	154	170	3.2	3.3	196	3.5	3.8

Shares outstanding: 6.51m at Aug 10, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.